Companies › Clover Biopharmaceuticals AUS
2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SCB-1022 Combination recombinant RSV-hMPV vaccine with protein subunit antigens from RSV A strain, | – | Phase 1 | RSV Infection | Mar 2028 |
| SCB-1033 Combination recombinant RSV-hMPV-PIV3 vaccine with protein subunit antigens from RSV A str | – | Phase 1 | RSV Infection | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06984094 | SCB-1022 | Phase 1 | RSV Infection | Infectious disease | Mar 2028 |
| NCT06984094 | SCB-1033 | Phase 1 | RSV Infection | Infectious disease | Mar 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.